Monday, November 23, 2009

Johnson & Johnson Itches for Successful Stelara Launch

Stelara (ustekinumab), the Johnson & Johnson (JNJ-$62.76) drug approved for the treatment of moderate-to-severe plaque psoriasis in adult patients, could be a blockbuster drug. This first-in-class interleukin (IL) inhibitor offers the appeal of fewer injections than the established biologics for psoriasis, the tumor necrosis factor-alpha inhibitors.

Commercial success of Stelara, however, could hinge on acceptance by dermatologists.
Which TNF-alpha inhibitor has the most to lose if Stelara changes prescribing habits—Humira or Enbrel? To find out, continue reading at BNET Pharma….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

No comments: